News

Aditx Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

SmallCaps Daily September 10, 2020

204 2 minutes read

Virtual Presentation
on Wednesday, September 16th at 3:00 PM EDT

Loma Linda, CA – (NewMediaWire) – September 10, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”)
(NASDAQ:ADTX), a life sciences company developing biotechnologies focused on
improving the health of the immune system through immune monitoring and
reprogramming, today announced that it will be presenting at the H.C.
Wainwright 22nd Annual Global Investment Conference being held virtually from
September 14-16, 2020. The presentation is scheduled for Wednesday, September
16th at 3:00 PM EDT.

Amro Albanna,
Co-founder and Chief Executive Officer of Aditxt, will be presenting a
corporate overview to a live audience and will be available for virtual
one-on-one meetings with investors throughout the conference.

The presentation will be webcast live and may
be accessed by following this link: https://wsw.com/webcast/hcw7/adtx/1609577

About Aditx Therapeutics

Aditxt is developing
technologies specifically focused on improving the health of the immune system
through immune monitoring and reprogramming. The immune monitoring technology
is designed to provide a personalized comprehensive profile of the immune
system. The immune reprogramming technology is currently at the pre-clinical
stage and is designed to retrain the immune system to induce tolerance with an
objective of addressing rejection of transplanted organs, autoimmune diseases,
and allergies. For more information, please visit www.aditxt.com.

Forward-Looking Statements

Certain statements in
this press release constitute “forward-looking statements” within the meaning
of the federal securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things, the Company’s ongoing and
planned product development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations regarding
product launch and revenue; the Company’s results of operations, cash needs,
spending, financial condition, liquidity, prospects, growth and strategies; the
industry in which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not guarantees of
future performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section entitled
“Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was
filed with the U.S. Securities and Exchange Commission under File No. 333-248491,
as well as discussions of potential risks, uncertainties, and other important
factors in the Company’s subsequent filings with the U.S. Securities and
Exchange Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise.